Cobra Biologics Wins Manufacturing Agreement to Produce Anaerobic Bacteria

29th February 2012 | Proteins

Cobra today announces that it has signed an agreement with a clinical stage biotechnology company to produce a Drug Substance under cGMP.

The product, consisting of live bacteria, will be used for toxicology and clinical studies for treatment of a metabolic disorder. The disorder is a rare genetic disease leading to kidney failure and end stage renal disease.

The newly aquired Cobra facility in Matfors, Sweden, has a long standing experience in large scale microbial production and will perform both the upstream and downstream work to isolate and purify the live bacteria.

Peter Coleman, CEO of Cobra Biologics said: "We are very pleased to have been selected by this company as this underlines Cobra's extensive experience and expertise in producing microbial based products for clinical trials through to commercial supply."

comments powered by Disqus
In order to provide complete functionality, this web site needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site. It is recommended that you allow all cookies. Allow all cookies